nodes	percent_of_prediction	percent_of_DWPC	metapath
Amoxapine—ORM1—Erlotinib—kidney cancer	0.138	0.255	CbGbCtD
Amoxapine—HTR2B—Sorafenib—kidney cancer	0.119	0.221	CbGbCtD
Amoxapine—HTR2C—Sorafenib—kidney cancer	0.0773	0.144	CbGbCtD
Amoxapine—CYP2D6—Temsirolimus—kidney cancer	0.0761	0.141	CbGbCtD
Amoxapine—CYP2D6—Pazopanib—kidney cancer	0.04	0.0742	CbGbCtD
Amoxapine—CYP2D6—Erlotinib—kidney cancer	0.0285	0.053	CbGbCtD
Amoxapine—CYP2D6—Sorafenib—kidney cancer	0.0232	0.0431	CbGbCtD
Amoxapine—CYP2D6—Vinblastine—kidney cancer	0.0229	0.0425	CbGbCtD
Amoxapine—CYP2D6—Doxorubicin—kidney cancer	0.0141	0.0261	CbGbCtD
Amoxapine—Asthenia—Vinblastine—kidney cancer	0.000539	0.00149	CcSEcCtD
Amoxapine—Fatigue—Sunitinib—kidney cancer	0.000539	0.00149	CcSEcCtD
Amoxapine—Asthenia—Everolimus—kidney cancer	0.000537	0.00149	CcSEcCtD
Amoxapine—Constipation—Sunitinib—kidney cancer	0.000535	0.00148	CcSEcCtD
Amoxapine—Acute coronary syndrome—Capecitabine—kidney cancer	0.000533	0.00148	CcSEcCtD
Amoxapine—Gastrointestinal pain—Sorafenib—kidney cancer	0.000531	0.00147	CcSEcCtD
Amoxapine—Hypertension—Gemcitabine—kidney cancer	0.000531	0.00147	CcSEcCtD
Amoxapine—Myocardial infarction—Capecitabine—kidney cancer	0.00053	0.00147	CcSEcCtD
Amoxapine—Pruritus—Everolimus—kidney cancer	0.00053	0.00147	CcSEcCtD
Amoxapine—Oedema—Vincristine—kidney cancer	0.000529	0.00147	CcSEcCtD
Amoxapine—Stomatitis—Capecitabine—kidney cancer	0.000527	0.00146	CcSEcCtD
Amoxapine—Jaundice—Capecitabine—kidney cancer	0.000527	0.00146	CcSEcCtD
Amoxapine—Alopecia—Paclitaxel—kidney cancer	0.000522	0.00145	CcSEcCtD
Amoxapine—Asthenia—Erlotinib—kidney cancer	0.000518	0.00144	CcSEcCtD
Amoxapine—Thrombocytopenia—Vincristine—kidney cancer	0.000518	0.00144	CcSEcCtD
Amoxapine—Urticaria—Sorafenib—kidney cancer	0.000516	0.00143	CcSEcCtD
Amoxapine—Decreased appetite—Dactinomycin—kidney cancer	0.000515	0.00143	CcSEcCtD
Amoxapine—Diarrhoea—Vinblastine—kidney cancer	0.000514	0.00143	CcSEcCtD
Amoxapine—Abdominal pain—Sorafenib—kidney cancer	0.000514	0.00142	CcSEcCtD
Amoxapine—Body temperature increased—Sorafenib—kidney cancer	0.000514	0.00142	CcSEcCtD
Amoxapine—Diarrhoea—Everolimus—kidney cancer	0.000512	0.00142	CcSEcCtD
Amoxapine—Gastrointestinal pain—Sunitinib—kidney cancer	0.000511	0.00142	CcSEcCtD
Amoxapine—Pruritus—Erlotinib—kidney cancer	0.000511	0.00142	CcSEcCtD
Amoxapine—Fatigue—Dactinomycin—kidney cancer	0.00051	0.00141	CcSEcCtD
Amoxapine—Flatulence—Paclitaxel—kidney cancer	0.000507	0.00141	CcSEcCtD
Amoxapine—Vascular purpura—Doxorubicin—kidney cancer	0.000505	0.0014	CcSEcCtD
Amoxapine—Tension—Paclitaxel—kidney cancer	0.000505	0.0014	CcSEcCtD
Amoxapine—Agranulocytosis—Capecitabine—kidney cancer	0.000504	0.0014	CcSEcCtD
Amoxapine—Anorexia—Vincristine—kidney cancer	0.000504	0.0014	CcSEcCtD
Amoxapine—Dysgeusia—Paclitaxel—kidney cancer	0.000504	0.0014	CcSEcCtD
Amoxapine—Oedema—Gemcitabine—kidney cancer	0.000502	0.00139	CcSEcCtD
Amoxapine—Nervousness—Paclitaxel—kidney cancer	0.0005	0.00139	CcSEcCtD
Amoxapine—Dizziness—Vinblastine—kidney cancer	0.000497	0.00138	CcSEcCtD
Amoxapine—Dizziness—Everolimus—kidney cancer	0.000495	0.00137	CcSEcCtD
Amoxapine—Abdominal pain—Sunitinib—kidney cancer	0.000494	0.00137	CcSEcCtD
Amoxapine—Body temperature increased—Sunitinib—kidney cancer	0.000494	0.00137	CcSEcCtD
Amoxapine—Diarrhoea—Erlotinib—kidney cancer	0.000494	0.00137	CcSEcCtD
Amoxapine—Hypotension—Vincristine—kidney cancer	0.000494	0.00137	CcSEcCtD
Amoxapine—Thrombocytopenia—Gemcitabine—kidney cancer	0.000491	0.00136	CcSEcCtD
Amoxapine—Feeling abnormal—Dactinomycin—kidney cancer	0.000488	0.00135	CcSEcCtD
Amoxapine—Hepatitis—Capecitabine—kidney cancer	0.000485	0.00134	CcSEcCtD
Amoxapine—Vision blurred—Paclitaxel—kidney cancer	0.000485	0.00134	CcSEcCtD
Amoxapine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000484	0.00134	CcSEcCtD
Amoxapine—Hypoaesthesia—Capecitabine—kidney cancer	0.000483	0.00134	CcSEcCtD
Amoxapine—Tremor—Paclitaxel—kidney cancer	0.000482	0.00134	CcSEcCtD
Amoxapine—Increased appetite—Doxorubicin—kidney cancer	0.000481	0.00133	CcSEcCtD
Amoxapine—Insomnia—Vincristine—kidney cancer	0.000478	0.00133	CcSEcCtD
Amoxapine—Anorexia—Gemcitabine—kidney cancer	0.000478	0.00133	CcSEcCtD
Amoxapine—Vomiting—Vinblastine—kidney cancer	0.000478	0.00132	CcSEcCtD
Amoxapine—Dizziness—Erlotinib—kidney cancer	0.000478	0.00132	CcSEcCtD
Amoxapine—Vomiting—Everolimus—kidney cancer	0.000476	0.00132	CcSEcCtD
Amoxapine—Desloratadine—ABCB1—kidney cancer	0.000476	0.371	CrCbGaD
Amoxapine—Paraesthesia—Vincristine—kidney cancer	0.000475	0.00132	CcSEcCtD
Amoxapine—Agitation—Paclitaxel—kidney cancer	0.000473	0.00131	CcSEcCtD
Amoxapine—Rash—Everolimus—kidney cancer	0.000472	0.00131	CcSEcCtD
Amoxapine—Dermatitis—Everolimus—kidney cancer	0.000472	0.00131	CcSEcCtD
Amoxapine—Headache—Vinblastine—kidney cancer	0.000471	0.0013	CcSEcCtD
Amoxapine—Purpura—Doxorubicin—kidney cancer	0.000469	0.0013	CcSEcCtD
Amoxapine—Headache—Everolimus—kidney cancer	0.000469	0.0013	CcSEcCtD
Amoxapine—Hypotension—Gemcitabine—kidney cancer	0.000469	0.0013	CcSEcCtD
Amoxapine—Body temperature increased—Dactinomycin—kidney cancer	0.000468	0.0013	CcSEcCtD
Amoxapine—Abdominal pain—Dactinomycin—kidney cancer	0.000468	0.0013	CcSEcCtD
Amoxapine—Asthenia—Sorafenib—kidney cancer	0.000466	0.00129	CcSEcCtD
Amoxapine—Syncope—Paclitaxel—kidney cancer	0.000462	0.00128	CcSEcCtD
Amoxapine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000461	0.00128	CcSEcCtD
Amoxapine—Leukopenia—Paclitaxel—kidney cancer	0.000461	0.00128	CcSEcCtD
Amoxapine—Decreased appetite—Vincristine—kidney cancer	0.00046	0.00127	CcSEcCtD
Amoxapine—Pruritus—Sorafenib—kidney cancer	0.00046	0.00127	CcSEcCtD
Amoxapine—Vomiting—Erlotinib—kidney cancer	0.000459	0.00127	CcSEcCtD
Amoxapine—Fatigue—Vincristine—kidney cancer	0.000456	0.00126	CcSEcCtD
Amoxapine—Rash—Erlotinib—kidney cancer	0.000455	0.00126	CcSEcCtD
Amoxapine—Dermatitis—Erlotinib—kidney cancer	0.000455	0.00126	CcSEcCtD
Amoxapine—Palpitations—Paclitaxel—kidney cancer	0.000455	0.00126	CcSEcCtD
Amoxapine—Insomnia—Gemcitabine—kidney cancer	0.000454	0.00126	CcSEcCtD
Amoxapine—Headache—Erlotinib—kidney cancer	0.000452	0.00125	CcSEcCtD
Amoxapine—Tinnitus—Capecitabine—kidney cancer	0.000452	0.00125	CcSEcCtD
Amoxapine—Loss of consciousness—Paclitaxel—kidney cancer	0.000452	0.00125	CcSEcCtD
Amoxapine—Constipation—Vincristine—kidney cancer	0.000452	0.00125	CcSEcCtD
Amoxapine—Paraesthesia—Gemcitabine—kidney cancer	0.00045	0.00125	CcSEcCtD
Amoxapine—Asthenia—Sunitinib—kidney cancer	0.000449	0.00124	CcSEcCtD
Amoxapine—Nausea—Vinblastine—kidney cancer	0.000446	0.00124	CcSEcCtD
Amoxapine—Somnolence—Gemcitabine—kidney cancer	0.000446	0.00124	CcSEcCtD
Amoxapine—Convulsion—Paclitaxel—kidney cancer	0.000446	0.00124	CcSEcCtD
Amoxapine—Nausea—Everolimus—kidney cancer	0.000445	0.00123	CcSEcCtD
Amoxapine—Diarrhoea—Sorafenib—kidney cancer	0.000445	0.00123	CcSEcCtD
Amoxapine—Hypertension—Paclitaxel—kidney cancer	0.000444	0.00123	CcSEcCtD
Amoxapine—Pruritus—Sunitinib—kidney cancer	0.000442	0.00123	CcSEcCtD
Amoxapine—Decreased appetite—Gemcitabine—kidney cancer	0.000436	0.00121	CcSEcCtD
Amoxapine—Fatigue—Gemcitabine—kidney cancer	0.000433	0.0012	CcSEcCtD
Amoxapine—Gastrointestinal pain—Vincristine—kidney cancer	0.000432	0.0012	CcSEcCtD
Amoxapine—Dizziness—Sorafenib—kidney cancer	0.00043	0.00119	CcSEcCtD
Amoxapine—Constipation—Gemcitabine—kidney cancer	0.000429	0.00119	CcSEcCtD
Amoxapine—Nausea—Erlotinib—kidney cancer	0.000429	0.00119	CcSEcCtD
Amoxapine—Alopecia—Capecitabine—kidney cancer	0.000429	0.00119	CcSEcCtD
Amoxapine—Dry mouth—Paclitaxel—kidney cancer	0.000429	0.00119	CcSEcCtD
Amoxapine—Diarrhoea—Sunitinib—kidney cancer	0.000428	0.00119	CcSEcCtD
Amoxapine—Ataxia—Doxorubicin—kidney cancer	0.000425	0.00118	CcSEcCtD
Amoxapine—Asthenia—Dactinomycin—kidney cancer	0.000425	0.00118	CcSEcCtD
Amoxapine—Confusional state—Paclitaxel—kidney cancer	0.000424	0.00117	CcSEcCtD
Amoxapine—Oedema—Paclitaxel—kidney cancer	0.00042	0.00116	CcSEcCtD
Amoxapine—Body temperature increased—Vincristine—kidney cancer	0.000418	0.00116	CcSEcCtD
Amoxapine—Abdominal pain—Vincristine—kidney cancer	0.000418	0.00116	CcSEcCtD
Amoxapine—Flatulence—Capecitabine—kidney cancer	0.000416	0.00115	CcSEcCtD
Amoxapine—Dysgeusia—Capecitabine—kidney cancer	0.000414	0.00115	CcSEcCtD
Amoxapine—Dizziness—Sunitinib—kidney cancer	0.000413	0.00115	CcSEcCtD
Amoxapine—Feeling abnormal—Gemcitabine—kidney cancer	0.000413	0.00115	CcSEcCtD
Amoxapine—Shock—Paclitaxel—kidney cancer	0.000413	0.00115	CcSEcCtD
Amoxapine—Vomiting—Sorafenib—kidney cancer	0.000413	0.00115	CcSEcCtD
Amoxapine—Thrombocytopenia—Paclitaxel—kidney cancer	0.000411	0.00114	CcSEcCtD
Amoxapine—Tachycardia—Paclitaxel—kidney cancer	0.00041	0.00114	CcSEcCtD
Amoxapine—Rash—Sorafenib—kidney cancer	0.00041	0.00114	CcSEcCtD
Amoxapine—Dermatitis—Sorafenib—kidney cancer	0.000409	0.00113	CcSEcCtD
Amoxapine—Headache—Sorafenib—kidney cancer	0.000407	0.00113	CcSEcCtD
Amoxapine—Diarrhoea—Dactinomycin—kidney cancer	0.000405	0.00112	CcSEcCtD
Amoxapine—Anorexia—Paclitaxel—kidney cancer	0.0004	0.00111	CcSEcCtD
Amoxapine—Vision blurred—Capecitabine—kidney cancer	0.000398	0.0011	CcSEcCtD
Amoxapine—Vomiting—Sunitinib—kidney cancer	0.000398	0.0011	CcSEcCtD
Amoxapine—Body temperature increased—Gemcitabine—kidney cancer	0.000397	0.0011	CcSEcCtD
Amoxapine—Tremor—Capecitabine—kidney cancer	0.000396	0.0011	CcSEcCtD
Amoxapine—Rash—Sunitinib—kidney cancer	0.000394	0.00109	CcSEcCtD
Amoxapine—Dermatitis—Sunitinib—kidney cancer	0.000394	0.00109	CcSEcCtD
Amoxapine—Hypotension—Paclitaxel—kidney cancer	0.000392	0.00109	CcSEcCtD
Amoxapine—Headache—Sunitinib—kidney cancer	0.000392	0.00109	CcSEcCtD
Amoxapine—Eosinophilia—Doxorubicin—kidney cancer	0.000387	0.00107	CcSEcCtD
Amoxapine—Nausea—Sorafenib—kidney cancer	0.000386	0.00107	CcSEcCtD
Amoxapine—Pancreatitis—Doxorubicin—kidney cancer	0.000383	0.00106	CcSEcCtD
Amoxapine—Insomnia—Paclitaxel—kidney cancer	0.00038	0.00105	CcSEcCtD
Amoxapine—Asthenia—Vincristine—kidney cancer	0.000379	0.00105	CcSEcCtD
Amoxapine—Syncope—Capecitabine—kidney cancer	0.000379	0.00105	CcSEcCtD
Amoxapine—Leukopenia—Capecitabine—kidney cancer	0.000378	0.00105	CcSEcCtD
Amoxapine—Paraesthesia—Paclitaxel—kidney cancer	0.000377	0.00105	CcSEcCtD
Amoxapine—Vomiting—Dactinomycin—kidney cancer	0.000376	0.00104	CcSEcCtD
Amoxapine—Somnolence—Paclitaxel—kidney cancer	0.000373	0.00104	CcSEcCtD
Amoxapine—Palpitations—Capecitabine—kidney cancer	0.000373	0.00103	CcSEcCtD
Amoxapine—Rash—Dactinomycin—kidney cancer	0.000373	0.00103	CcSEcCtD
Amoxapine—Nausea—Sunitinib—kidney cancer	0.000371	0.00103	CcSEcCtD
Amoxapine—Loss of consciousness—Capecitabine—kidney cancer	0.000371	0.00103	CcSEcCtD
Amoxapine—Dyspepsia—Paclitaxel—kidney cancer	0.00037	0.00102	CcSEcCtD
Amoxapine—Decreased appetite—Paclitaxel—kidney cancer	0.000365	0.00101	CcSEcCtD
Amoxapine—Hypertension—Capecitabine—kidney cancer	0.000365	0.00101	CcSEcCtD
Amoxapine—Fatigue—Paclitaxel—kidney cancer	0.000362	0.001	CcSEcCtD
Amoxapine—Diarrhoea—Vincristine—kidney cancer	0.000362	0.001	CcSEcCtD
Amoxapine—Pollakiuria—Doxorubicin—kidney cancer	0.000361	0.001	CcSEcCtD
Amoxapine—Asthenia—Gemcitabine—kidney cancer	0.00036	0.000998	CcSEcCtD
Amoxapine—Constipation—Paclitaxel—kidney cancer	0.000359	0.000996	CcSEcCtD
Amoxapine—Weight increased—Doxorubicin—kidney cancer	0.000356	0.000986	CcSEcCtD
Amoxapine—Pruritus—Gemcitabine—kidney cancer	0.000355	0.000984	CcSEcCtD
Amoxapine—Dry mouth—Capecitabine—kidney cancer	0.000352	0.000975	CcSEcCtD
Amoxapine—Nausea—Dactinomycin—kidney cancer	0.000352	0.000975	CcSEcCtD
Amoxapine—Dizziness—Vincristine—kidney cancer	0.00035	0.000969	CcSEcCtD
Amoxapine—Drowsiness—Doxorubicin—kidney cancer	0.000348	0.000966	CcSEcCtD
Amoxapine—Confusional state—Capecitabine—kidney cancer	0.000348	0.000963	CcSEcCtD
Amoxapine—Feeling abnormal—Paclitaxel—kidney cancer	0.000346	0.00096	CcSEcCtD
Amoxapine—Oedema—Capecitabine—kidney cancer	0.000345	0.000956	CcSEcCtD
Amoxapine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000343	0.000952	CcSEcCtD
Amoxapine—Diarrhoea—Gemcitabine—kidney cancer	0.000343	0.000952	CcSEcCtD
Amoxapine—Stomatitis—Doxorubicin—kidney cancer	0.00034	0.000941	CcSEcCtD
Amoxapine—Jaundice—Doxorubicin—kidney cancer	0.00034	0.000941	CcSEcCtD
Amoxapine—Shock—Capecitabine—kidney cancer	0.000339	0.00094	CcSEcCtD
Amoxapine—Thrombocytopenia—Capecitabine—kidney cancer	0.000337	0.000936	CcSEcCtD
Amoxapine—Tachycardia—Capecitabine—kidney cancer	0.000336	0.000933	CcSEcCtD
Amoxapine—Vomiting—Vincristine—kidney cancer	0.000336	0.000932	CcSEcCtD
Amoxapine—Urticaria—Paclitaxel—kidney cancer	0.000334	0.000925	CcSEcCtD
Amoxapine—Rash—Vincristine—kidney cancer	0.000333	0.000924	CcSEcCtD
Amoxapine—Dermatitis—Vincristine—kidney cancer	0.000333	0.000923	CcSEcCtD
Amoxapine—Body temperature increased—Paclitaxel—kidney cancer	0.000332	0.00092	CcSEcCtD
Amoxapine—Abdominal pain—Paclitaxel—kidney cancer	0.000332	0.00092	CcSEcCtD
Amoxapine—Headache—Vincristine—kidney cancer	0.000331	0.000918	CcSEcCtD
Amoxapine—Anorexia—Capecitabine—kidney cancer	0.000329	0.000911	CcSEcCtD
Amoxapine—Agranulocytosis—Doxorubicin—kidney cancer	0.000325	0.000901	CcSEcCtD
Amoxapine—Hypotension—Capecitabine—kidney cancer	0.000322	0.000893	CcSEcCtD
Amoxapine—Vomiting—Gemcitabine—kidney cancer	0.000319	0.000884	CcSEcCtD
Amoxapine—Rash—Gemcitabine—kidney cancer	0.000316	0.000877	CcSEcCtD
Amoxapine—Dermatitis—Gemcitabine—kidney cancer	0.000316	0.000876	CcSEcCtD
Amoxapine—Headache—Gemcitabine—kidney cancer	0.000314	0.000871	CcSEcCtD
Amoxapine—Nausea—Vincristine—kidney cancer	0.000314	0.000871	CcSEcCtD
Amoxapine—Hepatitis—Doxorubicin—kidney cancer	0.000313	0.000867	CcSEcCtD
Amoxapine—Insomnia—Capecitabine—kidney cancer	0.000312	0.000864	CcSEcCtD
Amoxapine—Hypoaesthesia—Doxorubicin—kidney cancer	0.000311	0.000863	CcSEcCtD
Amoxapine—Paraesthesia—Capecitabine—kidney cancer	0.00031	0.000858	CcSEcCtD
Amoxapine—Dyspepsia—Capecitabine—kidney cancer	0.000303	0.000841	CcSEcCtD
Amoxapine—Asthenia—Paclitaxel—kidney cancer	0.000301	0.000835	CcSEcCtD
Amoxapine—Decreased appetite—Capecitabine—kidney cancer	0.0003	0.000831	CcSEcCtD
Amoxapine—Nausea—Gemcitabine—kidney cancer	0.000298	0.000826	CcSEcCtD
Amoxapine—Fatigue—Capecitabine—kidney cancer	0.000297	0.000824	CcSEcCtD
Amoxapine—Pruritus—Paclitaxel—kidney cancer	0.000297	0.000824	CcSEcCtD
Amoxapine—Constipation—Capecitabine—kidney cancer	0.000295	0.000817	CcSEcCtD
Amoxapine—Tinnitus—Doxorubicin—kidney cancer	0.000292	0.000808	CcSEcCtD
Amoxapine—Diarrhoea—Paclitaxel—kidney cancer	0.000287	0.000797	CcSEcCtD
Amoxapine—Feeling abnormal—Capecitabine—kidney cancer	0.000284	0.000787	CcSEcCtD
Amoxapine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000282	0.000781	CcSEcCtD
Amoxapine—Dizziness—Paclitaxel—kidney cancer	0.000278	0.00077	CcSEcCtD
Amoxapine—Alopecia—Doxorubicin—kidney cancer	0.000276	0.000766	CcSEcCtD
Amoxapine—Urticaria—Capecitabine—kidney cancer	0.000274	0.000759	CcSEcCtD
Amoxapine—Body temperature increased—Capecitabine—kidney cancer	0.000272	0.000755	CcSEcCtD
Amoxapine—Abdominal pain—Capecitabine—kidney cancer	0.000272	0.000755	CcSEcCtD
Amoxapine—Flatulence—Doxorubicin—kidney cancer	0.000268	0.000744	CcSEcCtD
Amoxapine—Tension—Doxorubicin—kidney cancer	0.000267	0.000741	CcSEcCtD
Amoxapine—Vomiting—Paclitaxel—kidney cancer	0.000267	0.00074	CcSEcCtD
Amoxapine—Dysgeusia—Doxorubicin—kidney cancer	0.000267	0.000739	CcSEcCtD
Amoxapine—Rash—Paclitaxel—kidney cancer	0.000265	0.000734	CcSEcCtD
Amoxapine—Dermatitis—Paclitaxel—kidney cancer	0.000265	0.000733	CcSEcCtD
Amoxapine—Nervousness—Doxorubicin—kidney cancer	0.000264	0.000733	CcSEcCtD
Amoxapine—Headache—Paclitaxel—kidney cancer	0.000263	0.000729	CcSEcCtD
Amoxapine—Vision blurred—Doxorubicin—kidney cancer	0.000257	0.000711	CcSEcCtD
Amoxapine—Agitation—Doxorubicin—kidney cancer	0.00025	0.000694	CcSEcCtD
Amoxapine—Nausea—Paclitaxel—kidney cancer	0.000249	0.000692	CcSEcCtD
Amoxapine—Asthenia—Capecitabine—kidney cancer	0.000247	0.000686	CcSEcCtD
Amoxapine—Syncope—Doxorubicin—kidney cancer	0.000244	0.000677	CcSEcCtD
Amoxapine—Pruritus—Capecitabine—kidney cancer	0.000244	0.000676	CcSEcCtD
Amoxapine—Leukopenia—Doxorubicin—kidney cancer	0.000244	0.000676	CcSEcCtD
Amoxapine—Palpitations—Doxorubicin—kidney cancer	0.000241	0.000667	CcSEcCtD
Amoxapine—Loss of consciousness—Doxorubicin—kidney cancer	0.000239	0.000663	CcSEcCtD
Amoxapine—Convulsion—Doxorubicin—kidney cancer	0.000236	0.000654	CcSEcCtD
Amoxapine—Diarrhoea—Capecitabine—kidney cancer	0.000236	0.000654	CcSEcCtD
Amoxapine—Hypertension—Doxorubicin—kidney cancer	0.000235	0.000652	CcSEcCtD
Amoxapine—Dizziness—Capecitabine—kidney cancer	0.000228	0.000632	CcSEcCtD
Amoxapine—Dry mouth—Doxorubicin—kidney cancer	0.000227	0.000628	CcSEcCtD
Amoxapine—Confusional state—Doxorubicin—kidney cancer	0.000224	0.000621	CcSEcCtD
Amoxapine—Oedema—Doxorubicin—kidney cancer	0.000222	0.000616	CcSEcCtD
Amoxapine—Vomiting—Capecitabine—kidney cancer	0.000219	0.000608	CcSEcCtD
Amoxapine—Shock—Doxorubicin—kidney cancer	0.000219	0.000606	CcSEcCtD
Amoxapine—Thrombocytopenia—Doxorubicin—kidney cancer	0.000218	0.000603	CcSEcCtD
Amoxapine—Rash—Capecitabine—kidney cancer	0.000217	0.000602	CcSEcCtD
Amoxapine—Dermatitis—Capecitabine—kidney cancer	0.000217	0.000602	CcSEcCtD
Amoxapine—Tachycardia—Doxorubicin—kidney cancer	0.000217	0.000601	CcSEcCtD
Amoxapine—Headache—Capecitabine—kidney cancer	0.000216	0.000599	CcSEcCtD
Amoxapine—Anorexia—Doxorubicin—kidney cancer	0.000212	0.000587	CcSEcCtD
Amoxapine—Hypotension—Doxorubicin—kidney cancer	0.000208	0.000576	CcSEcCtD
Amoxapine—Nausea—Capecitabine—kidney cancer	0.000205	0.000568	CcSEcCtD
Amoxapine—Insomnia—Doxorubicin—kidney cancer	0.000201	0.000557	CcSEcCtD
Amoxapine—Paraesthesia—Doxorubicin—kidney cancer	0.0002	0.000553	CcSEcCtD
Amoxapine—Somnolence—Doxorubicin—kidney cancer	0.000198	0.000548	CcSEcCtD
Amoxapine—Dyspepsia—Doxorubicin—kidney cancer	0.000196	0.000542	CcSEcCtD
Amoxapine—Decreased appetite—Doxorubicin—kidney cancer	0.000193	0.000535	CcSEcCtD
Amoxapine—Fatigue—Doxorubicin—kidney cancer	0.000192	0.000531	CcSEcCtD
Amoxapine—Constipation—Doxorubicin—kidney cancer	0.00019	0.000527	CcSEcCtD
Amoxapine—Diazepam—PTGS1—kidney cancer	0.000186	0.145	CrCbGaD
Amoxapine—Feeling abnormal—Doxorubicin—kidney cancer	0.000183	0.000508	CcSEcCtD
Amoxapine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000182	0.000504	CcSEcCtD
Amoxapine—Urticaria—Doxorubicin—kidney cancer	0.000177	0.000489	CcSEcCtD
Amoxapine—Abdominal pain—Doxorubicin—kidney cancer	0.000176	0.000487	CcSEcCtD
Amoxapine—Body temperature increased—Doxorubicin—kidney cancer	0.000176	0.000487	CcSEcCtD
Amoxapine—Olanzapine—ABCB1—kidney cancer	0.000171	0.133	CrCbGaD
Amoxapine—Clozapine—CYP1A1—kidney cancer	0.000168	0.131	CrCbGaD
Amoxapine—Asthenia—Doxorubicin—kidney cancer	0.000159	0.000442	CcSEcCtD
Amoxapine—Pruritus—Doxorubicin—kidney cancer	0.000157	0.000436	CcSEcCtD
Amoxapine—Diarrhoea—Doxorubicin—kidney cancer	0.000152	0.000421	CcSEcCtD
Amoxapine—Dizziness—Doxorubicin—kidney cancer	0.000147	0.000407	CcSEcCtD
Amoxapine—Vomiting—Doxorubicin—kidney cancer	0.000141	0.000392	CcSEcCtD
Amoxapine—Rash—Doxorubicin—kidney cancer	0.00014	0.000388	CcSEcCtD
Amoxapine—Dermatitis—Doxorubicin—kidney cancer	0.00014	0.000388	CcSEcCtD
Amoxapine—Headache—Doxorubicin—kidney cancer	0.000139	0.000386	CcSEcCtD
Amoxapine—Nausea—Doxorubicin—kidney cancer	0.000132	0.000366	CcSEcCtD
Amoxapine—Quetiapine—ABCB1—kidney cancer	0.000104	0.0807	CrCbGaD
Amoxapine—Diazepam—ABCB1—kidney cancer	9.02e-05	0.0703	CrCbGaD
Amoxapine—Clozapine—ABCB1—kidney cancer	8.9e-05	0.0694	CrCbGaD
Amoxapine—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	9.1e-06	9.12e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—MAPK3—kidney cancer	9.08e-06	9.1e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—BRAF—kidney cancer	9.07e-06	9.1e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—CDKN1B—kidney cancer	9.07e-06	9.1e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—GSTM1—kidney cancer	9.07e-06	9.09e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	9.05e-06	9.07e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—POMC—kidney cancer	9.04e-06	9.07e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—POMC—kidney cancer	9.02e-06	9.05e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—IL2—kidney cancer	9e-06	9.02e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—POMC—kidney cancer	8.99e-06	9.02e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—PTEN—kidney cancer	8.98e-06	9e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—BRAF—kidney cancer	8.93e-06	8.95e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—BRAF—kidney cancer	8.91e-06	8.93e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	8.91e-06	8.93e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—VEGFA—kidney cancer	8.88e-06	8.91e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—BRAF—kidney cancer	8.88e-06	8.91e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—IL2—kidney cancer	8.88e-06	8.9e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—VEGFA—kidney cancer	8.87e-06	8.9e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—POMC—kidney cancer	8.85e-06	8.88e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—MAPK1—kidney cancer	8.8e-06	8.82e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—CCND1—kidney cancer	8.77e-06	8.8e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—JUN—kidney cancer	8.75e-06	8.78e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—BRAF—kidney cancer	8.74e-06	8.77e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	8.69e-06	8.72e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—CTNNB1—kidney cancer	8.69e-06	8.71e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	8.66e-06	8.68e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—CCND1—kidney cancer	8.65e-06	8.68e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	8.65e-06	8.67e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—KIT—kidney cancer	8.64e-06	8.67e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—APC—kidney cancer	8.64e-06	8.67e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—MAPK1—kidney cancer	8.64e-06	8.66e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—JUN—kidney cancer	8.64e-06	8.66e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—VEGFA—kidney cancer	8.63e-06	8.66e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—RAF1—kidney cancer	8.63e-06	8.65e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	8.61e-06	8.63e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—CYP1A1—kidney cancer	8.6e-06	8.62e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—RELA—kidney cancer	8.59e-06	8.62e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—RAF1—kidney cancer	8.58e-06	8.61e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—CTNNB1—kidney cancer	8.57e-06	8.59e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—RELA—kidney cancer	8.55e-06	8.57e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—ERBB2—kidney cancer	8.54e-06	8.56e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—VEGFA—kidney cancer	8.49e-06	8.52e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—ERBB2—kidney cancer	8.49e-06	8.52e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	8.48e-06	8.5e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—PTEN—kidney cancer	8.47e-06	8.49e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MTOR—kidney cancer	8.42e-06	8.45e-05	CbGpPWpGaD
Amoxapine—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	8.41e-06	8.43e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—MAPK3—kidney cancer	8.4e-06	8.43e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—MAPK3—kidney cancer	8.39e-06	8.42e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MTOR—kidney cancer	8.38e-06	8.41e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—PTEN—kidney cancer	8.35e-06	8.38e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—KRAS—kidney cancer	8.31e-06	8.33e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	8.28e-06	8.3e-05	CbGpPWpGaD
Amoxapine—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	8.27e-06	8.29e-05	CbGpPWpGaD
Amoxapine—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	8.25e-06	8.28e-05	CbGpPWpGaD
Amoxapine—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	8.23e-06	8.25e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—POMC—kidney cancer	8.23e-06	8.25e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—KRAS—kidney cancer	8.18e-06	8.2e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—MYC—kidney cancer	8.17e-06	8.2e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—MAPK3—kidney cancer	8.17e-06	8.19e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—MYC—kidney cancer	8.16e-06	8.19e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—KRAS—kidney cancer	8.16e-06	8.18e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—KRAS—kidney cancer	8.13e-06	8.15e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—BRAF—kidney cancer	8.12e-06	8.15e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—VEGFA—kidney cancer	8.11e-06	8.13e-05	CbGpPWpGaD
Amoxapine—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	8.1e-06	8.12e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—MAPK3—kidney cancer	8.04e-06	8.06e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	8e-06	8.03e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—MAPK1—kidney cancer	8e-06	8.02e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—MAPK1—kidney cancer	7.99e-06	8.01e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—MYC—kidney cancer	7.94e-06	7.96e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	7.91e-06	7.93e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	7.87e-06	7.9e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	7.87e-06	7.89e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PTGS2—kidney cancer	7.85e-06	7.87e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—MYC—kidney cancer	7.82e-06	7.84e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—MAPK1—kidney cancer	7.77e-06	7.79e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—IL2—kidney cancer	7.74e-06	7.76e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—IL2—kidney cancer	7.7e-06	7.72e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—MAPK3—kidney cancer	7.67e-06	7.69e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—VEGFA—kidney cancer	7.65e-06	7.67e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—MAPK1—kidney cancer	7.65e-06	7.67e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	7.63e-06	7.65e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—RAF1—kidney cancer	7.58e-06	7.6e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—KRAS—kidney cancer	7.55e-06	7.57e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—VEGFA—kidney cancer	7.54e-06	7.57e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—KRAS—kidney cancer	7.54e-06	7.56e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—RELA—kidney cancer	7.54e-06	7.56e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—CCND1—kidney cancer	7.54e-06	7.56e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—JUN—kidney cancer	7.53e-06	7.55e-05	CbGpPWpGaD
Amoxapine—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	7.52e-06	7.55e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	7.51e-06	7.53e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CCND1—kidney cancer	7.5e-06	7.52e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—ERBB2—kidney cancer	7.5e-06	7.52e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	7.49e-06	7.52e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—JUN—kidney cancer	7.49e-06	7.51e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	7.47e-06	7.49e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	7.47e-06	7.49e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—MYC—kidney cancer	7.46e-06	7.48e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—RAF1—kidney cancer	7.45e-06	7.48e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—RAF1—kidney cancer	7.44e-06	7.46e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	7.44e-06	7.46e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	7.43e-06	7.45e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—RELA—kidney cancer	7.42e-06	7.44e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—RAF1—kidney cancer	7.41e-06	7.44e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—RELA—kidney cancer	7.41e-06	7.43e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MTOR—kidney cancer	7.4e-06	7.42e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—RELA—kidney cancer	7.38e-06	7.4e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	7.38e-06	7.4e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—ERBB2—kidney cancer	7.36e-06	7.38e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	7.35e-06	7.37e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—KRAS—kidney cancer	7.34e-06	7.36e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—ERBB2—kidney cancer	7.34e-06	7.36e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	7.3e-06	7.32e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—MAPK1—kidney cancer	7.3e-06	7.32e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—PTEN—kidney cancer	7.28e-06	7.3e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MTOR—kidney cancer	7.28e-06	7.3e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—RELA—kidney cancer	7.27e-06	7.29e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MTOR—kidney cancer	7.26e-06	7.28e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—PTEN—kidney cancer	7.24e-06	7.26e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MTOR—kidney cancer	7.24e-06	7.26e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—MAPK3—kidney cancer	7.23e-06	7.25e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	7.22e-06	7.24e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—KRAS—kidney cancer	7.22e-06	7.24e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—MAPK3—kidney cancer	7.14e-06	7.16e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	7.13e-06	7.15e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—MYC—kidney cancer	7.04e-06	7.06e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—MYC—kidney cancer	6.94e-06	6.96e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CDKN1B—kidney cancer	6.94e-06	6.96e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—PIK3CA—kidney cancer	6.94e-06	6.96e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—PIK3CA—kidney cancer	6.93e-06	6.95e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—KRAS—kidney cancer	6.89e-06	6.91e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—MAPK1—kidney cancer	6.88e-06	6.9e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PTEN—kidney cancer	6.84e-06	6.86e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	6.83e-06	6.85e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	6.83e-06	6.85e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CDKN1B—kidney cancer	6.82e-06	6.83e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	6.79e-06	6.81e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—IL2—kidney cancer	6.79e-06	6.81e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—MAPK1—kidney cancer	6.79e-06	6.81e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—RAF1—kidney cancer	6.78e-06	6.8e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—RELA—kidney cancer	6.75e-06	6.77e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	6.74e-06	6.76e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—TP53—kidney cancer	6.71e-06	6.73e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	6.71e-06	6.73e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—TP53—kidney cancer	6.7e-06	6.72e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	6.69e-06	6.71e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—IL2—kidney cancer	6.68e-06	6.7e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—IL2—kidney cancer	6.67e-06	6.69e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—IL2—kidney cancer	6.65e-06	6.67e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—PIK3CA—kidney cancer	6.63e-06	6.65e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CCND1—kidney cancer	6.62e-06	6.64e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MTOR—kidney cancer	6.62e-06	6.64e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—JUN—kidney cancer	6.61e-06	6.63e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—VEGFA—kidney cancer	6.58e-06	6.59e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CTNNB1—kidney cancer	6.56e-06	6.58e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—IL2—kidney cancer	6.54e-06	6.56e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	6.54e-06	6.56e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—TP53—kidney cancer	6.52e-06	6.54e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CCND1—kidney cancer	6.52e-06	6.53e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—JUN—kidney cancer	6.5e-06	6.52e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CCND1—kidney cancer	6.5e-06	6.52e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—KRAS—kidney cancer	6.5e-06	6.52e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—JUN—kidney cancer	6.49e-06	6.51e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CCND1—kidney cancer	6.48e-06	6.5e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—JUN—kidney cancer	6.47e-06	6.49e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	6.45e-06	6.47e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CTNNB1—kidney cancer	6.44e-06	6.46e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	6.42e-06	6.44e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—TP53—kidney cancer	6.42e-06	6.44e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—KRAS—kidney cancer	6.41e-06	6.43e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—POMC—kidney cancer	6.41e-06	6.43e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PTEN—kidney cancer	6.39e-06	6.41e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	6.38e-06	6.4e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—JUN—kidney cancer	6.37e-06	6.38e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	6.33e-06	6.35e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	6.32e-06	6.34e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PTEN—kidney cancer	6.29e-06	6.31e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PTEN—kidney cancer	6.28e-06	6.29e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PTEN—kidney cancer	6.26e-06	6.27e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MAPK3—kidney cancer	6.22e-06	6.24e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	6.21e-06	6.23e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	6.19e-06	6.21e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	6.16e-06	6.18e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—TP53—kidney cancer	6.13e-06	6.14e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—IL2—kidney cancer	6.08e-06	6.1e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MYC—kidney cancer	6.05e-06	6.07e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MYC—kidney cancer	6.02e-06	6.04e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—PIK3CA—kidney cancer	5.97e-06	5.99e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CCND1—kidney cancer	5.93e-06	5.94e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MAPK1—kidney cancer	5.92e-06	5.94e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—JUN—kidney cancer	5.92e-06	5.93e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—PIK3CA—kidney cancer	5.89e-06	5.91e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	5.89e-06	5.9e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	5.87e-06	5.89e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—TP53—kidney cancer	5.78e-06	5.79e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—VEGFA—kidney cancer	5.77e-06	5.79e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PTEN—kidney cancer	5.72e-06	5.74e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—TP53—kidney cancer	5.7e-06	5.72e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	5.68e-06	5.7e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—VEGFA—kidney cancer	5.67e-06	5.68e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—VEGFA—kidney cancer	5.65e-06	5.67e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—KRAS—kidney cancer	5.59e-06	5.61e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	5.56e-06	5.58e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—KRAS—kidney cancer	5.56e-06	5.58e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MAPK3—kidney cancer	5.46e-06	5.48e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	5.37e-06	5.39e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MAPK3—kidney cancer	5.36e-06	5.38e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MAPK3—kidney cancer	5.34e-06	5.36e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MYC—kidney cancer	5.31e-06	5.33e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	5.26e-06	5.28e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MYC—kidney cancer	5.23e-06	5.24e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MYC—kidney cancer	5.22e-06	5.23e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MYC—kidney cancer	5.2e-06	5.21e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MAPK1—kidney cancer	5.2e-06	5.21e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	5.17e-06	5.18e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	5.14e-06	5.15e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MYC—kidney cancer	5.12e-06	5.13e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	5.11e-06	5.13e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PTGS2—kidney cancer	5.11e-06	5.13e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	5.11e-06	5.12e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MAPK1—kidney cancer	5.1e-06	5.12e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MAPK1—kidney cancer	5.09e-06	5.1e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	5.01e-06	5.02e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—TP53—kidney cancer	4.97e-06	4.98e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—TP53—kidney cancer	4.94e-06	4.96e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—KRAS—kidney cancer	4.91e-06	4.92e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	4.89e-06	4.9e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—KRAS—kidney cancer	4.83e-06	4.84e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PIK3CA—kidney cancer	4.83e-06	4.84e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—KRAS—kidney cancer	4.82e-06	4.83e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—KRAS—kidney cancer	4.8e-06	4.82e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MYC—kidney cancer	4.76e-06	4.77e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	4.73e-06	4.74e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	4.65e-06	4.66e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PIK3CA—kidney cancer	4.51e-06	4.52e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PTEN—kidney cancer	4.46e-06	4.47e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	4.44e-06	4.45e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PIK3CA—kidney cancer	4.43e-06	4.44e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	4.41e-06	4.43e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—KRAS—kidney cancer	4.39e-06	4.41e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—TP53—kidney cancer	4.36e-06	4.37e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	4.34e-06	4.36e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—TP53—kidney cancer	4.29e-06	4.3e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—TP53—kidney cancer	4.28e-06	4.3e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—TP53—kidney cancer	4.27e-06	4.28e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—TP53—kidney cancer	4.2e-06	4.21e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	4.04e-06	4.05e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—TP53—kidney cancer	3.9e-06	3.92e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CA—kidney cancer	3.15e-06	3.15e-05	CbGpPWpGaD
